New pill shows promise for rare childhood diseases
NCT ID NCT06153173
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing the drug mirdametinib in 40 people aged 2 and older with Langerhans cell histiocytosis or similar disorders. The goal is to see if this oral medication works better and has fewer side effects than current treatments. Participants take the drug twice daily for up to 13 cycles, and doctors will monitor response using scans and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mirdametinib (a pill taken by mouth twice daily)
- What this could lead to
- If successful, this could offer a more effective and less toxic treatment option for people with certain histiocytic disorders.
- What could go wrong
- This is a small, early-phase trial (40 participants) with no control group. The drug may not work as hoped or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTIC DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- New targeted drug combo aims to curb relapse in kids with rare immune disorder
- Scientists hunt for genetic clues in rare blood disorders
- New pill could spare kids with rare bone disease from chemo
- Cord blood transplants made more accessible for thousands with blood cancers
- Old drug, new hope: lenalidomide tackles rare histiocyte cancers